Additionally, HSYA may inhibit JAK2-mediated signaling, activating p-JAK2/p-STAT3 expression and subsequently suppressor of cytokine signalling-3 (SOCS-3), which provides negative feedback on p-JAK2/p-STAT3, aiding HSYA’s therapeutic effects on ischemic stroke (17). Here, JAK2 is linked to ischemic stroke.